Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOUBLIRI: Onivyde + Irinotecan in Advanced Cancer
NCT02640365Phase 1Completed
- Sponsor
- GERCOR
- Start
- Nov 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of irinotecan in cancer and colorectal cancer (CRC) (2 arms), sponsored by GERCOR. Primary endpoints: Adverse Event, Dose Limiting Toxicities at 28 days and 1 more. Started Nov 2015; status: completed.
02
Drugs
irinotecan
03
Conditions
cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02640365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02640365.